Anthem Biosciences Reports Q1FY27 Results: Revenue Stands at ₹4,182 Mn; EBITDA Margin Reaches 39.6%
Bengaluru: Anthem Biosciences Limited, a technology-focused Contract Research, Development and Manufacturing Organization (CRDMO), announced its unaudited Consolidated Financial Results for the quarter ended June 30, 2026. The company reported Consolidated Revenue from Operations at ₹4,182 Mn, while EBITDA was ₹1,755 Mn, translating to an EBITDA margin of 39.6%. Profit After Tax (PAT) was recorded at ₹1,199 Mn, reflecting a PAT margin of 27.1%.The company's performance across key business segments showed the following structure:
| Particulars (₹ Mn) | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 4,182 | 5,402 | -22.6% |
| CRDMO Business | 3,408 | 4,527 | -24.7% |
| Specialty Ingredients | 774 | 875 | -11.5% |
The consolidated revenues for the quarter stood at ₹4,431 Mn, down 21.3% year-on-year (YoY). EBITDA was reported at ₹1,755 Mn, compared to ₹2,143 Mn in Q1FY26. The company also reported that PBT (Profit before tax) was ₹1,446 Mn.
Financial details for the quarter are available in the table below:
| Metric | Value (₹ Mn) | Notes |
|---|---|---|
| Consolidated Revenue from Operations | 4,182 | |
| EBITDA | 1,755 | Margin: 39.6% |
| PAT (Profit After Tax) | 1,199 | Margin: 27.1% |
| Other Income | 249 | Includes forex gain and RoDTEP incentives |
| Financial and other Non-Operating Income | 236 |
Ajay Bhardwaj, Chairman, MD and CEO of Anthem Biosciences Limited, commented on the results, stating that Q1FY27 reflects timing shifts in deliveries to key customers. He added that underlying demand remains strong, allowing the company to capture momentum as scheduled deliveries concentrate in the latter half of the year.
Bhardwaj emphasized the firm commitment to sustaining revenue growth aligned with historical performance and highlighted improvements on the margin front across both EBITDA and PAT. He noted that a disciplined focus on cost efficiencies, yield optimization, and employee productivity is reinforcing the industry-leading margin profile, enabling them to sustain this performance through the fiscal year.
ANTHEM Stock Price Movement
Today, shares of Anthem Biosciences Limited edged higher to close at ₹794, gaining 0.31% in post-market trading. The stock maintained a tight session throughout the day, with volume reaching 648,680 shares after touching an intraday low of ₹784.15.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.